Apricus Expands Exclusive License Agreement With Sandoz Affiliate, Apricus to Receive Up to $63M in Milestone Payments

By: Benzinga
Apricus Biosciences (Nasdaq: APRI ) announced today that it has expanded its exclusive license agreement with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group (NYSE: NVS ) of Companies ("Sandoz"), for the commercialization of Vitaros®, indicated for the treatment of patients with erectile dysfunction
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.